机构:[1]National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China[2]Qilu Hospital, Shandong University, Jinan, China[3]Sun Yat-sen University Cancer Center, Guangzhou, China[4]Zhejiang Cancer Hospital, Zhejiang, China浙江省肿瘤医院[5]Chongqing University Cancer Hospital, Chongqing Cancer Institute and Chongqing Cancer Hospital, Chongqing, China[6]Cancer Hospital of Zhengzhou University (Henan Cancer Hospital), Zhengzhou, China河南省肿瘤医院[7]West China Second University Hospital, Sichuan, China[8]Fudan University Shanghai Cancer Center, Shanghai, China[9]The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China[10]The First Affiliated Hospital of Anhui Medical University, Hefei, China[11]The Fourth Hospital of Hebei Medical University, Shijiazhuang, China河北医科大学第四医院[12]Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China华中科技大学同济医学院附属协和医院[13]Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Zhejiang, China[14]Jiangsu Cancer Hospital, Nanjing, China[15]The First Affiliated Hospital of Xi'an Jiaotong University, Xian, China[16]Jiangxi Cancer Hospital, Nanchang, China[17]Shanghai General Hospital, Shanghai, China[18]Shanghai First Maternity and Infant Hospital, Shanghai, China[19]Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China[20]Nanchang University First Affiliated Hospital, Nanchang, China[21]Jiangsu Hengrui Medicine Co. Ltd., Shanghai, China
第一作者机构:[1]National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
推荐引用方式(GB/T 7714):
Li N.,Bu H.,Liu J.,et al.Efficacy and safety of oral poly (ADP-ribose) polymerase inhibitor fluzoparib in patients with BRCA1/2 mutations and recurrent ovarian cancer[J].GYNECOLOGIC ONCOLOGY.2020,159:159-159.doi:10.1016/j.ygyno.2020.05.229.
APA:
Li, N.,Bu, H.,Liu, J.,Zhu, J.,Zhou, Q....&Wu, L. Y..(2020).Efficacy and safety of oral poly (ADP-ribose) polymerase inhibitor fluzoparib in patients with BRCA1/2 mutations and recurrent ovarian cancer.GYNECOLOGIC ONCOLOGY,159,
MLA:
Li, N.,et al."Efficacy and safety of oral poly (ADP-ribose) polymerase inhibitor fluzoparib in patients with BRCA1/2 mutations and recurrent ovarian cancer".GYNECOLOGIC ONCOLOGY 159.(2020):159-159